Twelve biologics targeting cytokines TNF-α (tumor necrosis factor alpha), IL-12/23 (interleukin 12/23), IL-17 (interleukin 17), and IL-23 (interleukin 23) have been approved for the treatment of moderate to severe psoriasis in the United States, including most recently bimekizumab in October 2023 [1,2]. The gene discussed is TNF; the disease is psoriasis.